Biolevate Raises €30 Million to Automate Pharma Paperwork

Biolevate raised €30 million in Series A funding on 22 September 2026 to automate the regulatory paperwork that piles up after AI speeds drug discovery. The Paris company sells evidence-linked agents for dossiers, literature reviews and health-technology assessments, and it is opening a Boston office with the round.

RAISE France and Orange Ventures co-led the deal. Merck’s digital-health arm, Station F and EQT Ventures joined, a mix that looks more like an operations bet than a molecule hunt.

The Money Is Aimed at Regulatory Paperwork

Biolevate’s pitch is blunt about where the delay now sits. As models throw off more candidate drugs, someone still has to turn that science into files a regulator will accept. The company built an agentic platform that turns scientific and regulatory knowledge into workflows a person can audit, with each output tied back to source evidence and a human still required to sign off.

It says the system can run 100,000 agents at the same time. That figure is the industrial claim sitting under a product that started as help for medical writers and now spans research, clinical trials, health-technology assessments, regulatory dossiers and parts of discovery and development.

Joël Belafa, co-founder and chief executive, said customers are “increasingly embracing AI automation at scale, grounded in evidence and under rigorous human oversight.” The sentence is doing sales work, and it is also the constraint. A hallucinated citation can sink a filing. The buyers in this category will not take an agent that cannot show its working.

COMPANY-REPORTED TRACTION

• Literature reviews: Systematic reviews and research synthesis run 16 times faster, the company says.
• Regulatory intelligence: It claims an 80 per cent efficiency gain in intelligence and compliance work.
• Customers: More than a dozen enterprise accounts are in production.
• Recurring revenue: Annual recurring revenue rose 20-fold over the past 12 months; the starting figure was not disclosed.

Those numbers are the company’s own. It also lists Sanofi, NVIDIA and Microsoft among its partners. On its site, clinical protocol co-authoring is billed as 2 times faster, and clinical study report drafts as taking up to 50 per cent less first-draft effort, separate from Orange’s later claim on time-to-market.

Who Wrote the Series A Cheque?

The cap table is the tell. A French entrepreneur’s vehicle and a telecom’s venture arm co-led a life-sciences software round, then Merck’s digital-health fund stepped in beside a Paris campus investor and the seed backer.

THE SERIES A TABLE

Hénin, the entrepreneur behind RAISE France, said Biolevate is “turning the extraordinary potential of AI into trusted, evidence-grade automation that can operate at scale in regulated environments.” He takes the chair with the money.

Orange is not only writing a cheque. In a 22 September 2026 press release it said Orange Business will pair the platform with Enovalife, an Orange Business affiliate that already sells data and AI work into clinical research. The first joint targets are protocol development, clinical study reports and regulatory bridging across jurisdictions. Orange also said selected pharmaceutical processes have moved up to 50 per cent faster to market, a time-to-market figure that is not the same as Biolevate’s 50 per cent cut in CSR first-draft effort.

[PR] Orange strengthens its life sciences innovation ecosystem with investment in French health-tech start-up Biolevate https://t.co/uq01Sys5yt pic.twitter.com/iwExCPRXsF

— Orange Group Press Office (@OrangeGroupPR) September 22, 2026

The priority for pharmaceutical R&D organizations is no longer simply to test AI, but to deploy it at scale in ways that create value for teams and fit their operations.

Claire Scotton, Vice President, Healthcare and Life Sciences, Orange Business, 22 September 2026 press release

MSD Global Health Innovation Fund is the quiet industrial voter. The Merck & Co. unit describes itself as a $600 million evergreen digital-health fund, set up in 2010 in Rahway, New Jersey, to back software that eases biopharma operations. A drug maker’s venture arm putting money into dossier automation is a customer-class signal, not a discovery-lab one. It does not mean Merck is a disclosed Biolevate client.

Four Dataiku Alumni and a Coloplast Operator

The firm was founded in 2023 in Paris by people who had already shipped enterprise AI, then got stuck on the document pile that sits between a lab result and a marketed therapy. Belafa was director of engineering at Dataiku, the French AI software company, which he joined in 2015 as an early employee. Nathan Chen, the chief operating officer, came from Coloplast, the Danish medtech group. Belafa has said the two have been friends for 25 years and shared the same frustration with how slowly therapies reach patients.

THE FOUNDING BENCH

• Joël Belafa, CEO: Former Dataiku director of engineering; the public face of the round.
• Nathan Chen, COO: Operations and commercial lead, with a Coloplast background in pharma-adjacent process.
• Antoine De Torcy, chief AI officer: Ex-Dataiku business solutions manager, now running the model side.
• Anas Laaroussi, CTO: Former Dataiku engineer, in charge of the stack that has to keep 100,000 agents honest.

That Dataiku pedigree shows up in the product posture. The platform is built like enterprise software that a quality group can inspect, not like a chat window dropped on a shared drive. In a July 2026 interview Belafa also noted a European constraint that shapes the architecture: the company often cannot fine-tune on customer data, and sometimes nobody on the vendor side has even seen the files. Accuracy without that fine-tune is the hard engineering problem, which is why the firm talks about grounding every answer in cited evidence rather than a larger model.

Biolevate is in the 2025 French Tech 2030 cohort, the list of companies Paris treats as strategic for technological sovereignty. It has also been through Future4Care, the European AI-in-healthcare group Orange helped found. The political wrapping is French. The first foreign office is American.

McKinsey Puts $180 Million on Faster Filings

The paperwork bottleneck is not a startup talking point. In an August 2025 note, McKinsey argued that rewiring regulatory submissions with AI and a clean-sheet process could cut filing timelines from months to weeks and unlock as much as $180 million of net present value on a priority asset. The same note said only 13 per cent of companies automate, at scale, the formatting of tables, listings and figures, the dull work that still pads a dossier. A McKinsey project with Merck cut first-draft clinical study report writing from 180 hours to 80 hours and halved errors, according to that research.

Those hours are why a writing tool can raise Series A money. Discovery models make more candidates. Each candidate still needs protocols, study reports, literature reviews, safety updates and country-by-country bridging. Speed at the front of the chain without speed at the back just moves the queue.

Regulators have started to write the rules for that queue. In January 2025 the US Food and Drug Administration issued its first draft guidance on AI used to support decisions about a drug or biologic’s safety, effectiveness or quality. The document sets out a risk-based credibility assessment framework for each context of use, which is agency language for “show why this model is believable for this job.”

With the appropriate safeguards in place, artificial intelligence has transformative potential to advance clinical research and accelerate medical product development to improve patient care.

Robert M. Califf, M.D., then FDA commissioner, 6 January 2025 agency announcement

The safeguard the agency keeps repeating is a human in the loop. That matches Biolevate’s sales line and also caps it. The product cannot be a black box that files itself. It has to leave a trail a reviewer can walk, which is a slower kind of AI than the demos that raise money in other sectors, and a more sellable one inside a quality-assurance department.

Elise Began as Help for Medical Writers

Twenty-two months separate the seed and this Series A. The first product was narrower than the platform now on the homepage.

THE PATH FROM WRITING TOOL TO AGENT FLEET

1. 2015: Belafa joins Dataiku as an early employee and later runs engineering there.
2. 2023: Biolevate is founded in Paris around that writing bottleneck.
3. November 2024: EQT Ventures led their €6 million seed round for Elise, an assistant that used language models and document reading to help medical writers.
4. 2025: The company lands on the French Tech 2030 list and keeps expanding from writing into clinical, safety and market-access workflows.
5. 22 September 2026: The €30 million Series A closes, Hénin takes the chair, and Boston is named as the first office outside France.

Elise was a writer’s helper. The Series A company is selling a fleet. Biolevate has drafted seven patent applications across several therapeutic areas, with two already filed in Europe, and it has talked up an OCEAN discovery stack that can plug into NVIDIA’s BioNeMo agent tools. That discovery work is real in the marketing. The priced workflows on the public site are still the unglamorous ones: periodic safety update reports, batch-record checks, authority responses, HTA country adaptations, systematic literature reviews.

EQT knew Belafa from the Dataiku years. Julien Hobeika, a partner there, backed the seed on the medical-writing bottleneck, the same pile of documents that still sits at the centre of the Series A story. The product got wider. The job did not.

Boston Is the First Office Outside France

The new capital is earmarked for three things the company named in the announcement: international expansion, a deeper product, and larger deployments with life-sciences groups. Boston is the geographic piece of that list, a short train ride from a dense strip of US trial sponsors and a short flight from FDA reviewers who now have written AI guidance to point at.

WHERE THE ROUND IS MEANT TO GO

• A US beachhead: A Boston office, the first site outside France, timed with the close.
• A bigger bench: Headcount has already doubled over the past year to about 50 people, and the company expects to double again over the coming year.
• A wider filing: Seven patent applications drafted, two filed in Europe, across more than one therapeutic area.

The public conversation around the round was thin, which is normal for a B2B compliance tool. The one joke that attached itself treated the raise as if it had entered a clinical trial, a process crack that accidentally names the product. Biolevate is not selling a prettier chatbot. It is selling the next form in a chain of forms, with citations attached, at a volume a medical-writing group cannot staff.

Belafa’s other line from the Orange release is the mission version of the same idea: cut the time between a discovery that might save lives and the moment it reaches patients. The Boston lease and the new board seats are the visible change from a round that closed on 22 September 2026. The product the money buys is still a stack of dossiers that have to cite their sources, with a person on the hook for the last click.

Frequently Asked Questions

Who else is on Biolevate’s leadership team besides the founders?

Jerome Cabannes is chief revenue officer, with a background in biotech manufacturing and global expansion, and Florence Armstrong, PhD, is head of science. The company says an in-house science department uses every product it builds, a structure meant to keep the software tied to real study work rather than generic text tools.

How much had Biolevate raised before the Series A?

Angel backers in the November 2024 seed included Mehdi Ghissassi, then head of product at DeepMind, and the co-founders of Zoi, alongside bpifrance, on top of EQT Ventures’ lead. That seed was €6 million. Combined with the new round, total equity raised is €36 million.

What has the FDA published on AI used in drug filings?

The January 2025 draft was informed by more than 500 drug and biologic submissions with AI components since 2016, more than 800 public comments, and a Duke Margolis expert workshop. CDER and the European Medicines Agency later set out 10 guiding principles for AI in drug development, with human-centric design listed first.

Which product categories does Biolevate sell into besides pharmaceuticals?

Its public solutions list also covers medical devices, cosmetics and nutrition. The named workflows run from research and clinical work through market access, manufacturing batch-record quality control and periodic safety update reports, not only the original medical-writing job.

Disclaimer: This article is news reporting and analysis of a private financing round and of product claims made by the company and its investors. It is informational only and is not investment advice, a solicitation, or a recommendation to buy or sell any security or to award any vendor contract. It is also not medical, regulatory or legal advice and does not assess whether any drug, device, software tool or filing workflow is safe, effective or fit for a given use. Readers who are considering an investment, a procurement decision or a regulatory submission should consult a licensed financial adviser, a qualified regulatory-affairs professional or legal counsel before acting. Figures, headcount, customer counts and product metrics reflect company statements, investor pages and public guidance as of 22 September 2026 and may change.